Opendata, web and dolomites

miRNA-DisEASY SIGNED

microRNA biomarkers in an innovative biophotonic sensor kit for high-specific diagnosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 miRNA-DisEASY project word cloud

Explore the words cloud of the miRNA-DisEASY project. It provides you a very rough idea of what is the project "miRNA-DisEASY" about.

innovative    collaborations    validation    free    lung    experimental    diagnostic    detection    environment    academic    outputs    context    pathological    knowhow    universities    italy    biomarkers    parallel    since    2001    spain    genexplain    nowadays    small    illness    groups    regulation    huge    costly    destina    care    expression    forces    error    optimization    medical    integration    refined    site    continuing    showing    humans    trento    comprehension    molecules    optoi    parties    reliability    scientific    micrornas    semiconductor    decision    discovery    gene    created    manufacturing    close    cancer    nucleic    combined    bioinformatic    continue    network    amplifications    transcriptomics    mirna    kit    microelectronic    school    started    acid    joined    progress    genomics    tools    skills    companies    patented    granada    point    healthcare    detector    promise    disease    santa    microelectronics    turn    germany    noncoding    ethnic    mirnas    optical    technological    hannover    recognition    preparations    rna    chemical    sampling    respect    catarina    brazil    expressed    clinical   

Project "miRNA-DisEASY" data sheet

The following table provides information about the project.

Coordinator
OPTOELETTRONICA ITALIA SRL 

Organization address
address: VIA VIENNA 8
city: TRENTO
postcode: 38121
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.optoi.com/mirnadiseasy
 Total cost 490˙500 €
 EC max contribution 445˙500 € (91%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2015
 Funding Scheme MSCA-RISE
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OPTOELETTRONICA ITALIA SRL IT (TRENTO) coordinator 126˙000.00
2    UNIVERSITA DEGLI STUDI DI TRENTO IT (TRENTO) participant 126˙000.00
3    DESTINA GENOMICA ES (GRANADA) participant 112˙500.00
4    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 36˙000.00
5    UNIVERSIDAD DE GRANADA ES (GRANADA) participant 27˙000.00
6    GENEXPLAIN GMBH DE (WOLFENBUTTEL) participant 18˙000.00
7    UNIVERSIDADE FEDERAL DE SANTA CATARINA. BR (FLORIANOPOLIS) partner 0.00

Map

 Project objective

Since 2001’s discovery of microRNAs (miRNAs) in humans, progress in genomics and transcriptomics has increased our comprehension of gene expression regulation. miRNAs are small, noncoding RNA molecules showing huge promise as clinical biomarkers and diagnostic tools for illness and disease, as significant changes in their expression occur in response to pathological states. However, miRNA detection is still challenging nowadays, since costly, complex sample preparations and RNA amplifications are not yet reliable enough for clinical decision making. In this context, three innovative EU companies, Optoi Microelectronics - with microelectronic knowhow and manufacturing skills - DestiNA Genomics - with ‘error free’ chemical technology for microRNAs recognition – and GeneXplain – with bioinformatic capabilities - joined forces with four key academic research groups from the Universities of Trento (Italy), Granada (Spain), Hannover Medical School (Germany) and Santa Catarina (Brazil). All the parties combined their knowledge with respect to miRNA biomarkers with a particular focus on lung cancer, to develop a novel and reliable miRNA detection system for this disease. To this end, research collaborations will address the analysis of miRNAs specifically over-expressed in lung cancer, continuing experimental work already started in the past years, but with greater integration and focus. Existing close partnerships with healthcare institutions will be strengthened, ensuring multi-site and multi-ethnic sampling. In parallel, optimization and validation of a miRNA detection kit based on Optoi semiconductor optical detector will continue. The DestiNA patented technology for specific nucleic acid recognition will be refined to reach the integration and result reliability required for use in clinical point of care testing. The strong network created between the companies and the academic institutions will thus provide a unique scientific and technological environment to turn the research outputs into an innovative product for healthcare advance and progress.

 Deliverables

List of deliverables.
Report on training activities on management skills Documents, reports 2020-01-14 15:16:51
Report on outreach and communication activities Documents, reports 2020-01-14 15:16:33
Validation with clinical samples Documents, reports 2020-01-14 15:15:32
Report on lectures and techical training Documents, reports 2020-01-14 15:16:24
Organization of final conference Other 2020-01-14 15:16:49
Report on performance of miRNA biomarker in FFPE samples, fine-needle aspirate and sputum Documents, reports 2019-07-22 09:19:45
Report on common protocols for miRNA detection Documents, reports 2019-07-22 09:19:45
Project website launch Websites, patent fillings, videos etc. 2019-07-22 09:19:45

Take a look to the deliverables list in detail:  detailed list of miRNA-DisEASY deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Emilio Garcia-Fernandez, M. Carmen Gonzalez-Garcia, Salvatore Pernagallo, Maria J. Ruedas-Rama, Mario A. Fara, Francisco J. López-Delgado, James W. Dear, Hugh Ilyine, Cristina Ress, Juan J. Díaz-Mochón, Angel Orte
miR-122 direct detection in human serum by time-gated fluorescence imaging
published pages: , ISSN: 1359-7345, DOI: 10.1039/c9cc08069d
Chemical Communications 2019-12-16
2017 Simone Detassis, Margherita Grasso, Valerio Del Vescovo, Michela A. Denti
microRNAs Make the Call in Cancer Personalized Medicine
published pages: 1-20, ISSN: 2296-634X, DOI: 10.3389/fcell.2017.00086
Frontiers in Cell and Developmental Biology 5 2019-07-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRNA-DISEASY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRNA-DISEASY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

CONMECH (2019)

Nonsmooth Contact Dynamics

Read More  

VIDEC (2020)

Visualizing Death Inducing Protein Complexes

Read More  

MAIL (2019)

Identifying Marginal Lands in Europe and strengthening their contribution potentialities in a CO2sequestration strategy

Read More